World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

@article{Bandelow2002WorldFO,
  title={World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders},
  author={Borwin Bandelow and Joseph Zohar and Eric Hollander and Siegfried Kasper and Hans-J{\"u}rgen M{\"o}ller and WFSBP Task Force on Treatment Guidelines for Anxie},
  journal={The World Journal of Biological Psychiatry},
  year={2002},
  volume={3},
  pages={171 - 199}
}
  • B. Bandelow, J. Zohar, WFSBP Task Force on Treatment Guidelines for Anxie
  • Published 1 January 2002
  • Psychology, Medicine
  • The World Journal of Biological Psychiatry
Summary In this report, recommendations for the pharmacological treatment of anxiety and obsessive-compulsive disorders are presented, based on available randomized, placebo-or comparator-controlled clinical studies. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for panic disorder. Tri2-cyclk antidepressants (TCAs) are equally effective, but they are less well tolerated than the SSRIs. In treatment-resistant cases, benzodiazepines like alprazolam may be used when… 
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
  • B. BandelowJ. ZoharE. HollanderS. KasperH. MöllerWFSBP TASK FORCE ON TREATMENT GUIDELINES FOR ANXIE
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2008
TLDR
Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders.
  • B. BandelowC. Allgulander J. Zohar
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2022
TLDR
Recommendations for the treatment of panic disorder/agoraphobia (PDA), generalised anxiety disorder (GAD), social anxiety Disorder (SAD), specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism are provided.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD.
  • B. BandelowC. Allgulander J. Zohar
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2022
TLDR
Recommendations for the treatment of OCD and PTSD can be effectively treated with CBT and medications, and CBT is the psychotherapy modality with the best body of evidence.
Clinical uses of benzodiazepines. Focus on: benzodiazepines and anxiety disorders
TLDR
Benzodiazepines have proven very effective in panic disorder, generalized anxiety and, even if to a lower degree, in social phobia, and role in obsessive compulsive disorder and post traumatic stress disorder is not as strong but these medications may be useful for several patients with those diseases.
Treatment-Resistant Panic Disorder
TLDR
Recommendations for the treatment of patients with panic disorder and agoraphobia who do not respond to standard drugs, including selective serotonin reuptake inhibitors, tricyclic antidepressants, benzodiazepines, or irreversible monamine oxidase inhibitors are provided.
Evidence-based pharmacotherapy of Generalized Anxiety Disorder.
TLDR
Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative.
Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders
TLDR
It is suggested that initial BZDs treatment may prolong the overall DUI, although their prescription seems to be influenced by specific sociodemographic and clinical factors.
Evidence-based treatment of anxiety disorders
  • Dan J Stein
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2006
TLDR
The efficacy and tolerability of the SSRI, escitalopram, has been evaluated in patients with GAD and with SAD, and it exhibited a better tolerability profile, as assessed by discontinuation emergent signs and symptoms (DESS), in both patient groups.
Generalized anxiety disorder: how to treat, and for how long?
  • R. Lam
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2006
TLDR
Data from recent relapse-prevention studies and longer-term maintenance studies with paroxetine, venlafaxine and escitalopram strongly support the value of continued treatment for at least a further 6 months, and issues relating to the natural course of GAD are highlighted as important considerations to guide selection of pharmacotherapy.
Management of panic disorder
  • M. Lader
  • Psychology
    Expert review of neurotherapeutics
  • 2005
TLDR
Selective serotonin reuptake inhibitors are the first-line treatment for panic disorder, and tricyclic antidepressants are equally effective, but they are less well tolerated than the selective serotonin reptake inhibitors.
...
...

References

SHOWING 1-10 OF 649 REFERENCES
[The treatment of the resistant obsessive-compulsive disorder: an update].
TLDR
Preliminary evidence suggests that addition of low-dose dopamine antagonists appears to be a potentially useful strategy for the specific subgroup of OCD patients with a comorbid chromic tic disorder and possibly for those with concurrent psychotic spectrum disorders.
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
TLDR
The results of this preliminary, open-label trial suggest that olanzapine may be effective in augmenting ongoing SSRIs treatment for a portion of patients with obsessive-compulsive disorder refractory to SSRI treatment.
Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.
  • J. NelsonG. Chouinard
  • Medicine, Psychology
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique
  • 1999
Principles of benzodiazepine selection are outlined for various psychiatric indications and diverse populations (the elderly, and drug and alcohol abusers). Benzodiazepines are still among the most
Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.
TLDR
The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD.
Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
TLDR
The SRI sertraline was more effective in reducing MDD and OCD symptoms than the primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD.
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
TLDR
Patients with OCD and related disorders are not infrequently refractory to treatment with serotonin reuptake inhibitors and controlled trials of risperidone augmentation in such patients seem warranted, it is necessary to determine an appropriate dose range to minimize adverse effects.
On the Pharmacotherapy of Obsessive—Compulsive Disorder: Is a Consensus Possible?
TLDR
The available research evidence suggests that clomipramine possesses greater antiobsessional efficacy than do the SSRIs, and may be used as first-line treatments for OCD when properly used in small initial doses with gradual increases.
Olanzapine Augmentation of Serotonin Uptake Inhibitors in Obsessive—Compulsive Disorder: An Open Study
  • G. Francobandiera
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2001
TLDR
Olanzapine augmentation of SSRIs in treating OCD showed a good response rate, and it could therefore be considered as a treatment option when conventional therapies have failed.
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
TLDR
The suggestion that selective serotonin reuptake inhibitors possess efficacy similar to that of clomipramine, but have a superior side effect profile, may have important implications for patients with OCD who require long-term treatment.
...
...